<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="134635" id="root" date="1996-10-22" xml:lang="en">
<title>UK: INTERVIEW - SmithKline sees lower debt levels.</title>
<headline>INTERVIEW - SmithKline sees lower debt levels.</headline>
<dateline>LONDON 1996-10-22</dateline>
<text>
<p>Anglo-American drugs firm SmithKline Beechman said it plans to cut its debt levels in coming years, but it said the drive would not prevent it from making an acquisition if a good opportunity comes along.</p>
<p>&quot;We can reduce capital expenditure and we can improve our free cash flow and thereby will be able to reduce our debt levels,&quot; chief executive Jan Leschly told Reuters. &quot;On the other hand we are not too concerned (about the debt level).&quot;</p>
<p>SmithKline is striving to bring its gearing down to levels of around 50 percent after big investments in recent years pushed it up to 79 percent now.  </p>
<p>&quot;Obviously we would like to be below 100 (percent), but if a the right opportunity (to make an acquisition) comes up we will look at it,&quot; Leschly said.</p>
<p>&quot;We always look for new opportunities for new products,&quot; he said, while adding: &quot;We are, however, in the fortunate situation that we don't need to do anything.&quot;</p>
<p>But unlike rival Glaxo Wellcome, Leschly said he saw the current wave of mergers and acquisitions in the drug industry continuing unabatedly. &quot;The market is very competitive. The changes in healthcare reforms...mean many companies will have to look at opportunities on how to save costs,&quot; he said.  </p>
<p>SmithKline earlier reported a 20 percent rise in third quarter pre-tax profit to 374 million stg, coming in at the higher end of analysts' forecasts.</p>
<p>&quot;We have a great success in our new product sales,&quot; Leschly said, specifically pointing to the &quot;outstanding performance&quot; of SmithKline's anti-depressant drug Seroxat/Paxil.</p>
<p>The product saw worldwide sales rise by 54 percent to 189 million stg.</p>
<p>Antibiotic Augmentin, one of SmithKline's biggest-selling drugs, posted a sales increase of nine percent to 290 million stg, while raising its market share in Europe and in the U.S.  </p>
<p>Overall group sales grew 15 percent to 2.0 billion stg, led by an 80 percent volume rise in prescription drugs and a strong U.S. market.</p>
<p>&quot;This quarter was really extraordinary in terms of sales growth,&quot; Leschly said.</p>
<p>-- Hans de Jongh, London Newsroom +44 171 542 7717</p>
</text>
<copyright>(c) Reuters Limited 1996</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="UK">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-22"/>
  </code>
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-22"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-22"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C11">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-22"/>
  </code>
  <code code="C17">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-22"/>
  </code>
  <code code="C18">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-22"/>
  </code>
  <code code="C181">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-22"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-22"/>
  </code>
</codes>
<dc element="dc.date.created" value="1996-10-22"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1996-10-22"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="LONDON"/>
<dc element="dc.creator.location.country.name" value="UK"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
